| Autor: |
Ariana M. Chao, Jena S. Tronieri, Anastassia Amaro, Thomas A. Wadden |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Trends in Cardiovascular Medicine. 33:159-166 |
| ISSN: |
1050-1738 |
| Popis: |
Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chronic weight management. This paper reviews data on the mechanism of action, weight-loss and cardiometabolic efficacy, and safety of semaglutide 2.4 mg/week for obesity. Semaglutide has demonstrated the largest weight loss of any obesity medication to date with reductions of approximately 15% of initial weight at 68 weeks, accompanied by improvements in cardiovascular risks factors and physical functioning. The approval of this medication provides patients with greater options for weight management. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect